Invest with Confidence:
- Follow TipRanks' Top Wall Street Analysts to uncover their success rate and average return.
- Join thousands of data-driven investors – Build your Smart Portfolio for personalized insights.
Helius Medical Technologies ( (HSDT) ) has provided an update.
On January 21, 2025, Helius Medical Technologies entered into agreements with warrant holders to exercise existing warrants at a reduced price of $0.751 per share, generating approximately $3.7 million in gross proceeds. In exchange, the company issued new warrants, contingent on stockholder approval, for additional shares, impacting its financial strategy and necessitating subsequent stockholder meetings to ensure compliance with Nasdaq rules.
More about Helius Medical Technologies
Helius Medical Technologies is a leading neurotech company in the medical device field focused on neurologic deficits using orally applied technology. Their main product is the Portable Neuromodulation Stimulator (PoNS), which aids in improving balance and gait, particularly for patients with multiple sclerosis and other neurologic diseases.
YTD Price Performance: 11.43%
Average Trading Volume: 4,742,803
Technical Sentiment Consensus Rating: Buy
Current Market Cap: $2.91M
See more insights into HSDT stock on TipRanks’ Stock Analysis page.
